The antagonistic effect of decorin on Met signaling results in down-regulation of the major oncogene β-catenin and its downstream effector MYC (myelocytomatosis oncogene protein), both involved in the pathologies of various cancers (107, 114), and thus promotes an anti-tumorigenic activity of decorin (Figure 1). This evidence concerns the gene DCN and cancer.